Advertisement
Advertisement
IMTX
Immatics N.V. Ordinary Shares
6.36
USDSponsored
+0.18
+2.91%
Nov 06, 15:59 UTC -5
Closed
After-Market
6.36
0.00
0.00%
Immatics N.V. Ordinary Shares (IMTX) Earnings
IMTX Earnings Reports
Positive Surprise Ratio
IMTX beat 11 of 25 last estimates.
44%
Next Report
Date of Next Report
Nov 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.84M
/-$0.47
Implied change from Q2 26 (Revenue/ EPS)
+18.51%
/+2.17%
Implied change from Q3 25 (Revenue/ EPS)
+108.91%
/+11.90%
Immatics N.V. Ordinary Shares earnings per share and revenue
On Aug 18, 2026, IMTX reported earnings of -0.46 USD per share (EPS) for Q2 26, missing the estimate of -0.43 USD, resulting in a -5.70% surprise. Revenue reached 9.14 million, compared to an expected 10.89 million, with a -16.02% difference. The market reacted with a -1.73% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.47 USD, with revenue projected to reach 10.84 million USD, implying an increase of 2.17% EPS, and increase of 18.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Immatics N.V. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Immatics N.V. Ordinary Shares reported EPS of -$0.46, missing estimates by -5.7%, and revenue of $9.14M, -16.02% below expectations.
How did the market react to Immatics N.V. Ordinary Shares's Q2 2026 earnings?
The stock price moved down -1.73%, changed from $9.25 before the earnings release to $9.09 the day after.
When is Immatics N.V. Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 16, 2026.
What are the forecasts for Immatics N.V. Ordinary Shares's next earnings report?
Based on 7
analysts, Immatics N.V. Ordinary Shares is expected to report EPS of -$0.47 and revenue of $10.84M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.